| __timestamp | Mesoblast Limited | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 60987000 |
| Thursday, January 1, 2015 | 23783000 | 125542000 |
| Friday, January 1, 2016 | 29763000 | 210460000 |
| Sunday, January 1, 2017 | 12065000 | 275119000 |
| Monday, January 1, 2018 | 5508000 | 409539000 |
| Tuesday, January 1, 2019 | 75173000 | 547758000 |
| Wednesday, January 1, 2020 | 81497000 | 736300000 |
| Friday, January 1, 2021 | 85731000 | 904200000 |
| Saturday, January 1, 2022 | 63572000 | 1080300000 |
| Sunday, January 1, 2023 | 54922000 | 1262200000 |
| Monday, January 1, 2024 | 41070000 | 1530500000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. From 2014 to 2023, Vertex Pharmaceuticals Incorporated and Mesoblast Limited have showcased distinct financial trajectories. Vertex Pharmaceuticals, a leader in innovative therapies, has seen its cost of revenue surge by over 1,900%, peaking at approximately $1.26 billion in 2023. This reflects its aggressive expansion and investment in cutting-edge treatments. In contrast, Mesoblast Limited, a pioneer in regenerative medicine, experienced a more modest 61% increase, reaching around $54.9 million in 2023. This disparity highlights Vertex's robust market position and Mesoblast's strategic focus on niche markets. Notably, 2024 data for Vertex is absent, indicating potential shifts or reporting delays. As the pharmaceutical industry continues to innovate, these insights offer a glimpse into the financial strategies shaping the future of healthcare.
Cost of Revenue Comparison: Novo Nordisk A/S vs Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost Insights: Breaking Down Biogen Inc. and Mesoblast Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for Jazz Pharmaceuticals plc and Mesoblast Limited
Analyzing Cost of Revenue: Telix Pharmaceuticals Limited and Mesoblast Limited
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited